Business Context and Reporting Period
Envoy Medical, Inc. (Nasdaq: COCH) filed a Form 8-K on May 19, 2026, regarding its continued listing status on The Nasdaq Capital Market. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing compliance. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
The primary material event is the Company's failure to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for 30 consecutive business days. Although the initial 180-day compliance period expired on May 18, 2026, without the stock price meeting the requirement, Nasdaq granted the Company a second 180-day compliance period extending to November 16, 2026.
Guidance, Outlook, and Risks
Management Commentary and Plan: The Company intends to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. Nasdaq granted the extension based on the Company meeting all other listing requirements and providing written notice of its intent to cure the bid price deficiency.
Risks and Contingencies: The filing highlights risks related to the unpredictable nature of market trade prices and the substantial costs and diversion of management's attention required to address the listing deficiency. There is no guarantee that a reverse stock split will successfully allow the Company to meet the bid price requirement.
Investor Verification Checklist
- Verify the current trading price of Class A Common Stock (COCH) to assess the likelihood of meeting the $1.00 bid price requirement organically.
- Monitor for a formal proposal or shareholder vote regarding a reverse stock split, as this is the Company's stated cure mechanism.
- Confirm the Company's compliance with other Nasdaq listing requirements, specifically the market value of publicly held shares, which was cited as a factor in granting the extension.
- Review the Company's most recent Form 10-K for the year ended December 31, 2025, for detailed financial health and risk factors not included in this 8-K.